Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 22, 2022
September 22, 2022
d210019a-9b7e-4dde-8567-15304071541d
Related Documents
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry
Guidance DocumentSeptember 8, 2026Center for Drug Evaluation and Research
Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies
Guidance DocumentAugust 28, 2023Center for Drug Evaluation and Research
Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization
Guidance DocumentDecember 21, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.